Showing 37 to 48 of 123 results
Italy First to Offer Weekly Insulin via National Health Service
Italy becomes the first country to offer a new weekly insulin via its National Health Service, reducing annual injections for over 1.3 million insulin-treated patients from 365 to 52, improving quality of life and addressing significant adherence issues.
Italy First to Offer Weekly Insulin via National Health Service
Italy becomes the first country to offer a new weekly insulin via its National Health Service, reducing annual injections for over 1.3 million insulin-treated patients from 365 to 52, improving quality of life and addressing significant adherence issues.
Progress
52% Bias Score
Aloe Vera: Health Benefits and Risks
Aloe vera, originating in Africa, shows promise in wound healing, reducing plaque, and potentially managing blood sugar, though more research is needed, and its latex can cause adverse effects.
Aloe Vera: Health Benefits and Risks
Aloe vera, originating in Africa, shows promise in wound healing, reducing plaque, and potentially managing blood sugar, though more research is needed, and its latex can cause adverse effects.
Progress
24% Bias Score
High Sugar Consumption Accelerates Aging, Increases Disease Risk
Americans consume two to three times the recommended daily sugar, leading to accelerated aging through glycation, chronic inflammation, and mitochondrial dysfunction, increasing risks for various age-related diseases.
High Sugar Consumption Accelerates Aging, Increases Disease Risk
Americans consume two to three times the recommended daily sugar, leading to accelerated aging through glycation, chronic inflammation, and mitochondrial dysfunction, increasing risks for various age-related diseases.
Progress
56% Bias Score
GLP-1 Agonists Show Potential for Reducing Obesity-Related Cancer Risk
A new study of 170,030 obese and diabetic adults in the US found that GLP-1 receptor agonists (Ozempic, Wegovy, etc.) may modestly reduce the risk of 14 obesity-related cancers and all-cause mortality, especially in women, compared to DDP-4 inhibitors.
GLP-1 Agonists Show Potential for Reducing Obesity-Related Cancer Risk
A new study of 170,030 obese and diabetic adults in the US found that GLP-1 receptor agonists (Ozempic, Wegovy, etc.) may modestly reduce the risk of 14 obesity-related cancers and all-cause mortality, especially in women, compared to DDP-4 inhibitors.
Progress
44% Bias Score
Fructose, Diabetes, and Public Health in the Netherlands
Professor Martijn Brouwers's "Suiker in overvloed" examines the link between fructose consumption and the rise of diabetes and other health issues in the Netherlands, advocating for government intervention to address this growing problem.
Fructose, Diabetes, and Public Health in the Netherlands
Professor Martijn Brouwers's "Suiker in overvloed" examines the link between fructose consumption and the rise of diabetes and other health issues in the Netherlands, advocating for government intervention to address this growing problem.
Progress
28% Bias Score
Excessive Sugar Consumption: Historical Roots, Health Impacts, and Potential Solutions
The widespread consumption of sugar, originating from Arab introduction in the 7th and 8th centuries, now contributes to significant health problems like obesity and diabetes in many countries, leading to various interventions such as sugar taxes and behavioral therapies.
Excessive Sugar Consumption: Historical Roots, Health Impacts, and Potential Solutions
The widespread consumption of sugar, originating from Arab introduction in the 7th and 8th centuries, now contributes to significant health problems like obesity and diabetes in many countries, leading to various interventions such as sugar taxes and behavioral therapies.
Progress
44% Bias Score
GLP-1 RA Drugs May Double Macular Degeneration Risk in Diabetic Patients
A Canadian study of over 1 million Ontario residents with diabetes revealed that GLP-1 RA drugs, such as semaglutide and lixisenatide, may at least double the risk of developing neovascular age-related macular degeneration after six months of use, particularly in older patients or those with a histo...
GLP-1 RA Drugs May Double Macular Degeneration Risk in Diabetic Patients
A Canadian study of over 1 million Ontario residents with diabetes revealed that GLP-1 RA drugs, such as semaglutide and lixisenatide, may at least double the risk of developing neovascular age-related macular degeneration after six months of use, particularly in older patients or those with a histo...
Progress
48% Bias Score
Alarming Health Statistics of Mexican Schoolchildren Reveal Public Health Crisis
A health evaluation of 12 million Mexican schoolchildren reveals 39% are overweight, 38% have visual problems, and 59% have cavities; high sugar consumption is the primary cause, contributing to a public health crisis costing 650 billion pesos annually.
Alarming Health Statistics of Mexican Schoolchildren Reveal Public Health Crisis
A health evaluation of 12 million Mexican schoolchildren reveals 39% are overweight, 38% have visual problems, and 59% have cavities; high sugar consumption is the primary cause, contributing to a public health crisis costing 650 billion pesos annually.
Progress
44% Bias Score
iPSC-Based Therapies Show Promise in Treating Diabetes and Parkinson's Disease
Recent studies show iPSC-derived cells successfully treated diabetes and Parkinson's disease in small clinical trials, offering hope for regenerative medicine, although challenges in cost and scalability remain.
iPSC-Based Therapies Show Promise in Treating Diabetes and Parkinson's Disease
Recent studies show iPSC-derived cells successfully treated diabetes and Parkinson's disease in small clinical trials, offering hope for regenerative medicine, although challenges in cost and scalability remain.
Progress
36% Bias Score
FDA Ban on Compounded GLP-1 Drugs Restricts Access for Thousands
The FDA's ban on compounded GLP-1 medications, effective this week, will restrict access for thousands of patients who rely on these lower-cost alternatives for weight loss and diabetes, despite concerns about potential shortages and insurance coverage challenges.
FDA Ban on Compounded GLP-1 Drugs Restricts Access for Thousands
The FDA's ban on compounded GLP-1 medications, effective this week, will restrict access for thousands of patients who rely on these lower-cost alternatives for weight loss and diabetes, despite concerns about potential shortages and insurance coverage challenges.
Progress
60% Bias Score
FDA Ends Grace Period for Compounded GLP-1 Drugs, Raising Access Concerns
The FDA will end a grace period allowing the sale of compounded GLP-1 drugs for weight loss and diabetes, starting Thursday, impacting thousands of patients who rely on cheaper alternatives; brand-name drug shortages were declared over, leading to this decision.
FDA Ends Grace Period for Compounded GLP-1 Drugs, Raising Access Concerns
The FDA will end a grace period allowing the sale of compounded GLP-1 drugs for weight loss and diabetes, starting Thursday, impacting thousands of patients who rely on cheaper alternatives; brand-name drug shortages were declared over, leading to this decision.
Progress
56% Bias Score
Diabetes-Related Cardiovascular Deaths Rise in England
A Diabetes UK report reveals that 29% of cardiovascular deaths in England in 2022 were in people with diabetes, up from 15% in 2009, costing the UK £10.7bn annually with projected costs rising to £18bn by 2035, while only 61.3% received all recommended care processes.
Diabetes-Related Cardiovascular Deaths Rise in England
A Diabetes UK report reveals that 29% of cardiovascular deaths in England in 2022 were in people with diabetes, up from 15% in 2009, costing the UK £10.7bn annually with projected costs rising to £18bn by 2035, while only 61.3% received all recommended care processes.
Progress
36% Bias Score
Showing 37 to 48 of 123 results